SUMMARY OF PRODUCT CHARACTERISTICS

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1    NAME OF THE MEDICINAL PRODUCT

Luadei 13.5 mg intrauterine delivery system.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

The intrauterine delivery system contains 13.5 mg levonorgestrel.

For the full list of excipients, see section 6.1.

For details of release rates, see section 5.2.

3 PHARMACEUTICAL FORM

Intrauterine delivery system (IUS).

The product consists of a whitish or pale yellow drug core covered with a semiopaque membrane, which is mounted on the vertical stem of a T-body. In addition, the vertical stem contains a silver ring located close to the horizontal arms. The T-body has a loop at one end of the vertical stem and two horizontal arms at the other end. Removal threads are attached to the loop. The vertical stem of the IUS is loaded in the insertion tube at the tip of the inserter. The IUS and inserter are essentially free of visible impurities.

Dimensions of Luadei: 28 x 30 x 1.55 mm

4 CLINICAL PARTICULARS

Therapeutic indications

Contraception for up to 3 years.

4.2 Posology and method of administration

Posology

Luadei is inserted into the uterine cavity and is effective for up to three years. Insertion and removal/ replacement

It is recommended that Luadei should only be inserted by physicians/ healthcare providers who are experienced in IUS insertions and/ or have undergone training on the Luadei insertion procedure.

Luadei is to be inserted into the uterine cavity within seven days of the onset of menstruation. Luadei can be replaced by a new system at any time in the cycle.

Luadei can also be inserted immediately after first trimester abortion.

Postpartum insertions should be postponed until the uterus is fully involuted, however not earlier than six weeks after delivery. If involution is substantially delayed, consider waiting until 12 weeks postpartum.

In case of a difficult insertion and/ or exceptional pain or bleeding during or after insertion, appropriate steps should be taken immediately to exclude perforation, such as physical examination and ultrasound.

Luadei can be distinguished from other IUSs by the visibility of the silver ring on ultrasound. The T-frame of Luadei contains barium sulphate which makes it visible in X-ray examination.

Luadei is removed by gently pulling on the threads with a forceps. If the threads are not visible and the system is found to be in the uterine cavity on ultrasound exam, it may be removed using a narrow forceps. This may require dilatation of the cervical canal or surgical intervention.

The system should be removed no later than by the end of the third year. If the woman wishes to continue using the same method, a new system can be inserted immediately following removal of the original system.

If pregnancy is not desired, the removal should be carried out within 7 days of the onset of menstruation, provided the woman is still experiencing regular menses. If the system is removed at some other time during the cycle and the woman has had intercourse within a week, she is at risk of pregnancy unless a new system is inserted immediately following removal.

After removal of Luadei, the system should be examined to ensure that it is intact.

Elderly patients

Luadei has not been studied in women over the age of 65 years. There is no indication for the use of Luadei in postmenopausal women.

Patients with hepatic impairment

Luadei has not been studied in women with hepatic impairment. Luadei is contraindicated in women with acute liver disease or liver tumor (see section 4.3).

Patients with renal impairment

Luadei has not been studied in women with renal impairment.

Paediatric population

Safety and efficacy has not been studied in women aged below 18. Use of this product before menarche is not indicated.

Method of administration

To be inserted by a healthcare provider using aseptic technique.

Luadei is supplied within an inserter in a sterile package, which should not be opened until needed for insertion. Do not resterilize. As supplied, Luadei is for single use only. Do not use if the blister is damaged or open. Do not insert after the expiry date which is stated on the carton and the blister after EXP.

Any unused product or waste material should be disposed of in accordance with local requirements.

Preparation for insertion

-    Examine the patient to establish the size and position of the uterus, in order to detect any signs of acute genital infections or other contraindications for the insertion of Luadei. If there is any doubt regarding pregnancy, a pregnancy test should be performed.

-    Insert a speculum, visualize the cervix, and then thoroughly cleanse the cervix and vagina with a suitable antiseptic solution.

-    Employ an assistant as necessary.

-    Grasp the anterior lip of the cervix with a tenaculum or other forceps to stabilize the uterus. If the uterus is retroverted, it may be more appropriate to grasp the posterior lip of the cervix. Gentle traction on the forceps can be applied to straighten the cervical canal. The forceps should remain in position and gentle counter traction on the cervix should be maintained throughout the insertion procedure.

-    Advance a uterine sound through the cervical canal to the fundus to measure the depth and confirm the direction of the uterine cavity and to exclude any evidence of intrauterine abnormalities (e.g., septum, submucous fibroids) or a previously inserted intrauterine contraceptive which has not been removed. If difficulty is encountered, consider dilatation of the canal. If cervical dilatation is required, consider using analgesics and/or a paracervical block.

2. Push the slider forward in the

direction of the arrow to the furthest position to load Luadei into the insertion tube (Figure 2).

IMPORTANT! Do not pull the slider downwards as this may prematurely release Luadei. Once released, Luadei cannot be re-loaded.

3. Holding the slider in the furthest position, set the upper edge of the flange to correspond to the sound measurement of the uterine depth (Figure 3).

4. While holding the slider in the furthest position, advance the inserter through the cervix until the flange is approximately 1.5-2.0 cm from the uterine cervix (Figure 4).

IMPORTANT! Do not force the inserter. Dilate the cervical canal, if necessary.

5. While holding the inserter steady, pull the slider to the mark to open the horizontal arms of Luadei (Figure 5). Wait 5 -10 seconds for the horizontal arms to open completely.

6. Advance the inserter gently towards the fundus of the uterus until the flange touches the cervix. Luadei is now in the fundal position (Figure 6).

7. Holding the inserter in place, release Luadei by pulling the slider all the way down (Figure 7). While holding the slider all the way down, gently remove the inserter by pulling it out. Cut the threads to leave about 2-3 cm visible outside of the cervix.

IMPORTANT! Should you suspect that the system is not in the correct position, check placement (e.g. with ultrasound). Remove the system if it is not positioned properly within the uterine cavity. A removed system must not be re-inserted.

Removal/ replacement

For removal/ replacement, please see section 4.2 Insertion and removal/ replacement.

Luadei is removed by pulling on the threads with a forceps (Figure 8).

You may insert a new Luadei immediately following removal.

After removal of Luadei, the system should be examined to ensure that it is intact.

4.3    Contraindications

-    Pregnancy (see section 4.6);

-    Acute or recurrent pelvic inflammatory disease or conditions associated with increased risk for pelvic infections;

-    Acute cervicitis or vaginitis;

-    Postpartum endometritis or infected abortion during the past three months;

-    Cervical intraepithelial neoplasia until resolved;

-    Uterine or cervical malignancy;

-    Progestogen-sensitive tumours, e.g. breast cancer;

-    Abnormal vaginal bleeding of unknown etiology;

-    Congenital or acquired uterine anomaly including fibroids which would interfere with insertion and / or retention of the intrauterine system (i.e. if they distort the uterine cavity);

-    Acute liver disease or liver tumour;

-    Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Luadei should be used with caution after specialist consultation, or removal of the system should be considered if any of the following conditions exist or arise for the first time:

-    migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia

-    exceptionally severe headache

-    jaundice

-    marked increase of blood pressure

-    severe arterial disease such as stroke or myocardial infarction

Low-dose levonorgestrel may affect glucose tolerance, and the blood glucose concentration should be monitored in diabetic users of Luadei. However, there is generally no need to alter the therapeutic regimen in diabetics using LNG IUS.

Medical examination/ consultation

Before insertion, a woman must be informed of the benefits and risks of Luadei, including the risk of ectopic pregnancy, see below. A physical examination including pelvic examination, examination of the breasts, and a cervical smear should be performed. Pregnancy and sexually transmitted diseases should be excluded. Genital infections should be successfully treated prior to insertion. The position of the uterus and the size of the uterine cavity should be determined. Fundal positioning of Luadei is important in order to maximize the efficacy and reduce the risk of expulsion. The instructions for the insertion should be followed carefully.

Emphasis should be given to training in the correct insertion technique.

Insertion and removal may be associated with some pain and bleeding. The procedure may precipitate a vasovagal reaction (e.g. syncope, or a seizure in an epileptic patient).

A woman should be re-examined 4 to 6 weeks after insertion to check the threads and ensure that the system is in the correct position. Follow-up visits are recommended once a year thereafter, or more frequently if clinically indicated.

Luadei is not for use as a post-coital contraceptive.

The use of Luadei for the treatment of heavy menstrual bleeding or protection from endometrial hyperplasia during estrogen replacement therapy has not been established. Therefore it is not recommended for use in these conditions.

Ectopic pregnancy

In clinical trials, the overall incidence of ectopic pregnancy with Luadei was approximately 0.11 per 100 woman-years. Approximately half of the pregnancies that occur during Luadei use are likely to be ectopic.

Women considering Luadei should be counselled on the signs, symptoms and risks of ectopic pregnancy. For women who become pregnant while using Luadei, the possibility of an ectopic pregnancy must be considered and evaluated.

Women with a previous history of ectopic pregnancy, tubal surgery or pelvic infection carry an increased risk of ectopic pregnancy. The possibility of ectopic pregnancy should be considered in the case of lower abdominal pain, especially in connection with missed periods or if an amenorrheic woman starts bleeding.

Because an ectopic pregnancy may impact future fertility the benefits and risks of using Luadei should be carefully evaluated, in particular for nulliparous women.

Use in nulliparous women: Luadei is not first choice for contraception in nulliparous women as clinical experience is limited.

Effects on the menstrual bleeding pattern

Effects on the menstrual bleeding pattern are expected in most users of Luadei. Those alterations are a result of the direct action of levonorgestrel on the endometrium and may not correlate with the ovarian activity.

Irregular bleeding and spotting are common in the first months of use. Thereafter, the strong suppression of the endometrium results in the reduction of the duration and volume of menstrual bleeding. Scanty flow frequently develops into oligomenorrhea or amenorrhea.

In clinical trials, infrequent bleeding and/ or amenorrhea developed gradually in about 22.3 % and 11.6 % of the users, respectively. Pregnancy should be considered if menstruation does not occur within six weeks of the onset of previous menstruation.

A repeated pregnancy test is not necessary in subjects who remain amenorrheic unless indicated by other signs of pregnancy.

If bleeding becomes heavier and/ or more irregular over time, appropriate diagnostic measures should be taken as irregular bleeding may be a symptom of endometrial polyps, hyperplasia or cancer and heavy bleeding may be a sign of unnoticed expulsion of the IUS.

Pelvic infection

While Luadei and the inserter as such are sterile they may, due to bacterial contamination during insertion, become a vehicle for microbial transport in the upper genital tract. Pelvic infection has been reported during use of any IUS or IUD. In clinical trials, pelvic inflammatory disease (PID) was observed more frequently at the beginning of Luadei use, which is consistent with published data for copper IUDs, where the highest rate of PID occurs during the first 3 weeks after insertion and decreases thereafter.

Before electing use of Luadei, patients should be fully evaluated for risk factors associated with pelvic infection (e.g. multiple sexual partners, sexually transmitted infections, prior history of PID). Pelvic infections such as PID may have serious consequences and it may impair fertility and increase the risk of ectopic pregnancy.

As with other gynaecological or surgical procedures, severe infection or sepsis (including group A streptococcal sepsis) can occur following IUD insertion, although this is extremely rare.

If a woman experiences recurrent endometritis or pelvic inflammatory disease or if an acute infection is severe or does not respond to treatment, Luadei must be removed.

Bacteriological examinations are indicated and monitoring is recommended, even with discrete symptoms indicative of infections.

Expulsion

In clinical trials with Luadei, the incidence of expulsion was low and in the same range as that reported for other IUDs and IUSs. Symptoms of the partial or complete expulsion of Luadei may include bleeding or pain. However, partial or complete expulsion can occur without the woman noticing it, leading to decrease or loss of contraceptive protection. As Luadei typically decreases menstrual bleeding over time, an increase of menstrual bleeding may be indicative of an expulsion.

A partially expelled Luadei should be removed. A new system can be inserted at that time provided pregnancy has been excluded.

A woman should be advised how to check the threads of Luadei and to contact her healthcare provider if the threads cannot be felt.

Perforation

Perforation or penetration of the uterine corpus or cervix by an intrauterine contraceptive may occur rarely, most often during insertion and may decrease the effectiveness of Luadei. In case of a difficult insertion and/ or exceptional pain or bleeding during or after insertion, appropriate steps should be taken immediately to exclude perforation, such as physical examination and ultrasound. Such a system must be removed. The risk of perforations is increased in breast-feeding women and may be increased in post-partum insertions (see section 4.2), and in women with a fixed retroverted uterus.

Lost threads

If the removal threads are not visible at the cervix on follow-up examinations, unnoticed expulsion and pregnancy must be excluded. The threads may have been drawn up into the uterus or cervical canal and may reappear during the next menstrual period. If pregnancy has been excluded, the threads may usually be located by gently probing the cervical canal with a suitable instrument. If they cannot be found, the system may have been expelled. Ultrasound exam may be used to ascertain the position of the system. If ultrasound is not available or is not successful, X-ray may be used to locate Luadei.

Ovarian cysts / enlarged ovarian follicles

Since the contraceptive effect of Luadei is mainly due to its local effects within the uterus, there is generally no change in ovulatory function, including regular follicular development, oocyte release and follicular atresia in women of fertile age. Sometimes atresia of the follicle is delayed and folliculogenesis may continue. These enlarged follicles cannot be distinguished clinically from ovarian cysts and have been reported in clinical trials as adverse drug events in approximately 13.2 % of women using Luadei including ovarian cyst, hemorrhagic ovarian cyst and ruptured ovarian cyst. Most of these cysts are asymptomatic, although some may be accompanied by pelvic pain or dyspareunia.

In most cases, the enlarged follicles resolve spontaneously over two to three months observation. Should an enlarged follicle fail to resolve spontaneously, continued ultrasound monitoring and other diagnostic/ therapeutic measures may be appropriate. Rarely, surgical intervention may be required.

4.5 Interaction with other medicinal products and other forms of interaction

Interactions can occur with drugs that induce hepatic microsomal enzymes, specifically cytochrome P450 enzymes, and may therefore increase the metabolism of levonorgestrel, resulting in increased clearance of sex hormones (e.g. phenytoin, barbiturates, primidone, carbamazepine, rifampicin, rifabutin, nevirapine, efavirenz, bosentan, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin and products containing the herbal remedy St. John’s Wort).

On the other hand, substances known to inhibit drug-metabolizing enzymes (e.g. itraconazole, ketoconazole) may increase serum concentrations of levonorgestrel.

The influence of these drugs on the efficacy of Luadei is not known, but it is not believed to be of major importance due to the local mechanism of action.

Magnetic resonance imaging (MRI)

Non-clinical testing has demonstrated that a patient can be scanned safely after placement of Luadei under the following conditions: Static magnetic field of 3-Tesla or less, maximum spatial gradient magnetic field of 720-Gauss/cm or less. Under these conditions, with 15-min of scanning, the maximum temperature rise produced at the site of Luadei was 1.8°C. A small amount of imaging artifact may occur if the area of interest is in the exact same area or relatively close to the position of Luadei.

4.6 Fertility, pregnancy and lactation

Fertility

The use of a levonorgestrel-releasing intrauterine system does not alter the course of future fertility. Upon removal of the intrauterine system, women return to their normal fertility (see section 5.1).

Pregnancy

The insertion of Luadei in pregnant women is contraindicated (see section 4.3).

If a woman becomes pregnant while using Luadei ectopic pregnancy should be excluded and timely removal of the system is recommended since any intrauterine contraceptive left in situ may increase the risk of abortion and preterm labor. Removal of Luadei or probing of the uterus may also result in spontaneous abortion. If the woman wishes to continue the pregnancy and the system cannot be withdrawn, she should be informed about the risks and the possible consequences of premature birth to the infant. The course of such a pregnancy should be closely monitored. The woman should be instructed to report all symptoms that suggest complications of the pregnancy, like cramping abdominal pain with fever.

Because of the intrauterine administration and the local exposure to LNG, the possible occurrence of virilizing effects in a female fetus should be taken into consideration. Clinical experience of the outcomes of pregnancies under Luadei treatment is limited due to the high contraceptive efficacy. Women should be

informed that, to date, there is no evidence of birth defects caused by a levonorgestrel-releasing intrauterine system use in cases where pregnancy has continued to term with the LNG-IUS in place.

Breastfeeding

In general, there appears to be no deleterious effect on infant growth or development when using any progestogen-only method after six weeks postpartum. A levonorgestrel-releasing intrauterine system does not affect the quantity or quality of breast milk. Small amounts of progestogen (about 0.1 % of the levonorgestrel dose) pass into the breast milk in nursing mothers.

4.7 Effects on ability to drive and use machines

Luadei has no influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The majority of women experience changes in menstrual bleeding pattern after insertion of Luadei. Over time, the frequency of amenorrhoea and infrequent bleeding increases, and the frequency of both prolonged and frequent bleeding decreases. The following bleeding patterns were observed in clinical trials:

Table 1: Bleeding patterns reported with Luadei in clinical trials

Luadei	First 90 days	Second 90 days	End of year 1	End of year 3
Amenorrhea	<1%	3%	6%	12%
Infrequent bleeding	8%	19%	20%	22%
Frequent bleeding	31%	12%	8%	4%
Prolonged bleeding*	59%	17%	9%	3%

*Subjects with prolonged bleeding may also be included in one of the other categories (excluding amenorrhea)

Tabulated summary of adverse events

The frequencies of Adverse Drug Reactions (ADRs) reported with Luadei are summarized in the table below. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as: very common (> 1/10), common (> 1/100 to < 1/10), uncommon (> 1/1,000 to < 1/100),

rare (> 1/10,000 to < 1/1,000), very rare (< 1/10,000).

System Organ Class	Very Common	Common	Uncommon	Rare
Psychiatric disorders		Depressed mood/ Depression
Nervous system disorders	Headache	Migraine
Gastrointestinal disorders	Abdominal/pelvic pain	Nausea
Skin and subcutaneous tissue disorders	Acne/ Seborrhoea	Alopecia	Hirsutism
Reproductive system and breast disorders	Bleeding changes including increased and decreased menstrual bleeding, spotting, infrequent bleeding and amenorrhoea Ovarian cyst* Vulvovaginitis	Upper genital tract infection Dysmenorrhea Breast pain/discomfort Device expulsion (complete and partial) Genital discharge		Uterine perforation

* In clinical trials ovarian cysts had to be reported as AEs if they were abnormal, non-functional cysts and/or had a diameter > 3 cm on ultrasound examination.

Description of selected adverse reactions

With the use of another LNG-IUS, cases of hypersensitivity including rash, urticaria and angioedema have been reported.

If a woman becomes pregnant while using Luadei, the relative likelihood of this pregnancy being ectopic is increased (see section 4.4 under Ectopic Pregnancy).

The removal threads may be felt by the partner during intercourse.

Clinical trials with Luadei excluded breast-feeding women. A large post authorization safety study with other IUDs/IUSs shows an increased risk of perforation in breastfeeding women (see section 4.4 under Perforation).

The following ADRs have been reported in connection with the insertion or removal procedure of Luadei: Procedural pain, procedural bleeding, insertion-related vasovagal reaction with dizziness or syncope. The procedure may precipitate a seizure in an epileptic patient.

For other IUDs, cases of sepsis (including group A streptococcal sepsis) have been reported following insertion (see section 4.4 under Pelvic Infection).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard

4.9 Overdose

Not relevant.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Plastic IUD with progestogen, ATC code: G02BA03

Pharmacodynamic effects

Luadei has mainly local progestogenic effects in the uterine cavity.

The high levonorgestrel concentration in the endometrium down-regulates endometrial estrogen and progesterone receptors. The endometrium becomes relatively insensitive to the circulating estradiol and a strong antiproliferative effect is seen. Morphological changes of the endometrium and a weak local foreign body reaction are observed during use. Thickening of the cervical mucus prevents passage of the sperm through the cervical canal. The local milieu of the uterus and of the fallopian tubes inhibits sperm mobility and function, preventing fertilization. In clinical trials with Luadei ovulation was observed in the majority of the subjects studied. Evidence of ovulation was seen in 34 out of 35 women in the first year, in 26 out of 27 women in the second year, and in all 27 women in the third year.

Clinical efficacy and safety

The contraceptive efficacy of Luadei has been evaluated in a clinical study with 1432 women aged 18-35 including 38.8 % (556) nulliparous women of whom 83.6% (465) were nulligravid using Luadei. The 1-year Pearl Index was 0.41 (95% confidence limits 0.13 - 0.96) and the 3-years Pearl Index was 0.33 (95% confidence limits 0.16 - 0.60). The failure rate was approximately 0.4% at 1 year and the cumulative failure rate was approximately 0.9% at 3 years. The failure rate also includes pregnancies occurring after undetected expulsions and perforations. Use of a levonorgestrel releasing intrauterine system does not alter the course of future fertility. Based on data with a higher dosed LNG-IUS about 80% of the women wishing to become pregnant conceived within 12 months after removal of the system.

With Luadei, the alterations in menstrual patterns are a result of the direct action of levonorgestrel on the endometrium and may not reflect the ovarian cycle. There is no clear difference in follicle development, ovulation or estradiol and progesterone production in women with different bleeding patterns. In the process of inhibition of the endometrial proliferation, there can be an initial increase of spotting during the first months of use. Thereafter, the strong suppression of the endometrium results in the reduction of the duration and volume of menstrual bleeding during use of Luadei. Scanty flow frequently develops into oligomenorrhea or amenorrhea. Ovarian function remains normal and estradiol levels are maintained, even when users of Luadei are amenorrhoeic.

5.2 Pharmacokinetic properties

Levonorgestrel is released locally into the uterine cavity. The in vivo release curve is characterized by an initial steep decline that slows down progressively resulting in little change after 1 year until the end of the intended 3-year period of use. Estimated in vivo delivery rates for different time points are provided in Table 2.

Table 2: Estimated in vivo release rates based on observed ex vivo residual content data

Time	Estimated in vivo release rate [micrograms/24 hours]
24 days after insertion	14
60 days after insertion	10
1 year after insertion	6
3 years after insertion	5
Average over 3 years	6

Absorption

Following insertion, levonorgestrel is released from the IUS into the uterine cavity without delay based on serum concentration measurements. Maximum serum concentrations of levonorgestrel are reached within the first two weeks after insertion of Luadei. Seven days after insertion, a mean levonorgestrel concentration of 162 pg/ml was determined. Thereafter serum concentrations of levonorgestrel decline over time to reach mean concentrations of 59 pg/ml after 3 years. With the use of a levonorgetrel-releasing intrauterine system, the high local drug exposure in the uterine cavity leads to a strong concentration gradient from the endometrium to the myometrium (gradient endometrium to myometrium >100-fold), and to low concentrations of levonorgestrel in serum (gradient endometrium to serum >1000-fold).

Distribution

Levonorgestrel is bound non-specifically to serum albumin and specifically to SHBG. Less than 2 % of the circulating levonorgestrel is present as free steroid. Levonorgestrel binds with high affinity to SHBG. Accordingly, changes in the concentration of SHBG in serum result in an increase (at higher SHBG concentrations) or in a decrease (at lower SHBG concentrations) of the total levonorgestrel concentration in serum. Within one month after insertion of Luadei, the concentration of SHBG declines by about 30%. Thereafter, plateau-like SHBG concentrations are observed with a tendency to increase towards baseline values over time. The mean apparent volume of distribution of levonorgestrel is about 106 L.

Biotransformation

Levonorgestrel is extensively metabolized. The major metabolites in plasma are the unconjugated and conjugated forms of 3a, 5^-

tetrahydrolevonorgestrel. Based on in vitro and in vivo studies, CYP3A4 is the main enzyme involved in the metabolism of levonorgestrel.

Elimination

The total clearance of levonorgestrel from plasma is approximately 1.0 ml/min/kg. Only trace amounts of levonorgestrel are excreted in unchanged form. The metabolites are excreted in feces and urine at an excretion ratio of about 1. The excretion half-life is about 1 day.

Linearity/ non-linearity

The pharmacokinetics of levonorgestrel are dependent on the concentration of SHBG which itself is influenced by estrogens and androgens. During the first month of use of Luadei, a mean SHBG decrease of about 30 % is observed which leads to a decrease of levonorgestrel in serum indicating non-linear pharmacokinetics of levonorgestrel with regard to time. Based on the mainly local action of Luadei, no impact on the efficacy of Luadei is expected.

5.3 Preclinical safety data

Nonclinical data revealed no special hazard for humans based on studies of safety pharmacology, pharmacokinetics and toxicity, including genotoxicity and carcinogenic potential of levonorgestrel. Studies in monkeys with intrauterine delivery of levonorgestrel for 9 to 12 months confirmed local pharmacological activity with good local tolerance and no signs of systemic toxicity. No embryotoxicity was seen in the rabbit following intrauterine administration of levonorgestrel. The safety evaluation of the elastomer components of the hormone reservoir, the polyethylene materials of the product, the silver profile and the combination of elastomer and levonorgestrel, based on both the assessment of genetic toxicology in standard in vitro and in vivo test systems and on biocompatibility tests in mice, rats, guinea pigs, rabbits and in vitro test systems have not revealed bioincompatibility.

6.1 List of excipients

Polydimethylsiloxane elastomer

Silica, colloidal anhydrous

Polyethylene

Barium sulfate

Iron oxide, black (E172)

Silver

6.2 Incompatibilities

Not applicable.

6.3    Shelf life

3 years.

6.4    Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

The product is individually packed into a thermoformed blister package (PETG) with a peelable lid (PE).

Pack sizes: 1x1 and 5x1.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

The product is supplied in a sterile pack which should not be opened until required for insertion. Each system should be handled with aseptic precautions. If the seal of the sterile envelope is broken, the system inside should be disposed of in accordance with local guidelines for the handling of biohazardous waste. Likewise, a removed Luadei and inserter should be disposed of in this manner. The outer carton package and the inner blister package can be handled as household waste.

To be inserted by a healthcare provider using aseptic technique (see section 4.2).

MARKETING AUTHORISATION HOLDER

Bayer plc, Bayer House, Strawberry Hill, Newbury, Berkshire,

RG14 1JA

8    MARKETING AUTHORISATION NUMBER(S)

PL 00010/0588

9    DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

25/01/2013

10    DATE OF REVISION OF THE TEXT

03/04/2014